Fennec Pharmaceuticals Inc. (NASDAQ:FENC) on Tuesday shared topline results from the investigator-initiated Phase 2/3 STS-J01 trial of Pedmark (sodium thiosulfate injection) to reduce cisplatin-induced ototoxicity in pediatric and adolescent and young adult patients with non-metastatic solid…
Continue reading...